Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

738

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

March 31, 2008

Conditions
Rhinitis, Allergic, Seasonal
Interventions
BIOLOGICAL

Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate

Escalating doses, 6 weekly subcutaneous (under the skin) injections

BIOLOGICAL

Histamine base

Escalating doses, 6 weekly subcutaneous (under the skin) injections

Trial Locations (28)

19013

Asthma & Allergy Research Associates, Upland

27262

Allergy & Asthma Center, High Point

30281

Atlanta Allergy & Asthma Clinic, Stockbridge

Clinical Research of Atlanta, Stockbridge

36203

Center Of Research Excellence, Oxford

44718

Allergy & Respiratory Center, Canton

45231

Bernstein Clinical Research Center, Cincinnati

46208

Research Center of Indiana, Indianapolis

53209

Advanced Healthcare, Milwaukee

53228

Asthma, Allergy & Sinus Center, Greenfield

53792

University of Wisconsin Madison Medical School, Madison

55416

Asthma and Allergy Research Center, Minneapolis

55441

Clinical Research Institute, Plymouth

61761

Sneeze, Wheeze, and Itch Associates, Normal

63141

Clinical Research Center, St Louis

64093

Clinical Research of the Ozarks, Warrensburg

65203

Clinical Research of the Ozarks, Columbia

65401

Clinical Research of The Ozarks, Rolla

68046

Asthma & Allergy Center, Papillion

68130

Midwest Allergy & Asthma Clinic, Omaha

68131

Creighton University, Omaha

73120

Allergy, Asthma and Clinical Research Center, Oklahoma City

75231

AARA Research Center, Dallas

Pharmaceutical Research & Consulting, Dallas

78028

Kerrville Allergy and Asthma Associates, Kerrville

78130

Central Texas Health Research, New Braunfels

78229

Sylvana Research, San Antonio

08558

Princeton Center for Clinical Research, Skillman

All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY